Survey: Pharma CEOs on the importance of technology, demographics and innovation

7 February 2014
pwc-big

A global survey of chief executives has revealed the priorities and concerns of pharmaceutical and life sciences CEOs.

The survey by PricewaterhouseCoopers (PwC) included 1,344 CEOs in 68 countries. It found that pharmaceuticals and life sciences (PLS) CEOs believe that technology is transforming the sector and they’re using strength in innovation to make the most of it. Compared to CEOs in other sectors, they are even more convinced than their peers that technological advances will transform their businesses in the next five years believing that technology will help more than hinder. Only around a third of sector CEOs are concerned that the speed of technological change may negatively impact growth, compared to nearly half of CEOs across the overall sample.

Demographics

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology